NHS rejected new drug designed to slow down Alzheimer’s

Tarin Rahman

Today’s news on 23rd October, it has been reported the NHS will not fund the new drug Donanebab that will slow down Alzheimer’s disease. The new drug is reported to be too expensive for its benefit, although being considered as the turning point for the common disease.  

The National Institute of Health and Care Excellence (NICE) said the drug will only be giving patients small benefits. The reports have stated that the new drug is not a cure for Alzheimer’s, but to lessen the progression of the disease.